NewAmsterdam Pharma Co N.V. (NAMS)

NASDAQ: NAMS · IEX Real-Time Price · USD
8.50
-0.01 (-0.06%)
At close: Dec 6, 2022 3:46 PM
8.55
+0.06 (0.65%)
After-hours: Dec 6, 2022 4:00 PM EST
-0.06%
Market Cap 732.07M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out n/a
EPS (ttm) 0.44
PE Ratio 19.31
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 45,215
Open 8.45
Previous Close 8.5
Day's Range 8 - 8.98
52-Week Range 7.52 - 32.88
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About NAMS

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands. [Read more]

Industry Biotechnology
Founded 2019
Employees 8
Stock Exchange NASDAQ
Ticker Symbol NAMS
Full Company Profile

News

NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral ...

-- Business combination transaction with Frazier Lifesciences Acquisition Corporation, a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners, completed on Novemb...

1 week ago - GlobeNewsWire

Frazier Lifesciences Acquisition Corporation Shareholders Approve Business Combination with NewAmsterdam Pharma Holdi...

MENLO PARK, Calif.--( BUSINESS WIRE )--Frazier Lifesciences Acquisition Corporation (Nasdaq: FLAC) (“FLAC”), a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partner...

3 weeks ago - Business Wire